bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Expansion of CCR8+ Inflammatory Myeloid Cells in Cancer Patients with Urothelial and Renal Carcinomas
Authors: Eruslanov Evgeniy , Stoffs Taryn , Kim Wan-Ju , Daurkin Irina , Gilbert Scott M. , Su Li-Ming , Vieweg Johannes , Daaka Yehia , Kusmartsev Sergei
Published: April 2023

PDF file - 410K, Calcium influx in myeloid cells induced by CCL1 and SDF1
Data Supplement from Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts
Authors: Cottu Paul , Bièche Ivan , Assayag Franck , El Botty Rania , Chateau-Joubert Sophie , Thuleau Aurélie , Bagarre Thomas , Albaud Benoit , Rapinat Audrey , Gentien David , de la Grange Pierre , Sibut Vonick , Vacher Sophie , Hatem Rana , Servely Jean-Luc , Fontaine Jean-Jacques , Decaudin Didier , Pierga Jean-Yves , Roman-Roman Sergio , Marangoni Elisabetta
Published: April 2023

Supplementary Table S6. Genes differentially expressed between HBCx34 TamR and HBCx34 and associated gene ontology terms.
Supplementary Figures Legends from High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer
Authors: Alves Carla L. , Elias Daniel , Lyng Maria , Bak Martin , Kirkegaard Tove , Lykkesfeldt Anne E. , Ditzel Henrik J.
Published: April 2023

Legends to Supplementary Figures S1-S3.
Supplementary figure 3 from TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Authors: Peeters Sarah G.J.A. , Zegers Catharina M.L. , Biemans Rianne , Lieuwes Natasja G. , van Stiphout Ruud G.P.M. , Yaromina Ala , Sun Jessica D. , Hart Charles P. , Windhorst Albert D. , van Elmpt Wouter , Dubois Ludwig J. , Lambin Philippe
Published: April 2023

Supplementary figure 3. A) Tumor growth of rhabdomyosarcoma bearing animals (n=8) treated with TH-302 (25mg/kg) in combination with 4, 8 or 12Gy of RT. Data represent mean {plus minus} SEM. B) T4xSV for rhabdomyosarcoma bearing animals treated with TH-302 in combination with RT 0, 4, 8 or 12Gy. C) T4xSV for rhabdomyosarcoma bearing animals exposed to different oxygen concentrations in combination with TH-302 and RT. D) T4xSV for H460 bearing animals exposed to different oxygen concentrations in combination with TH-302 and RT.
Supplementary Figure 1 from Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
Authors: Parry Marina , Rose-Zerilli Matthew J.J. , Ljungström Viktor , Gibson Jane , Wang Jun , Walewska Renata , Parker Helen , Parker Anton , Davis Zadie , Gardiner Anne , McIver-Brown Neil , Kalpadakis Christina , Xochelli Aliki , Anagnostopoulos Achilles , Fazi Claudia , Gonzalez de Castro David , Dearden Claire , Pratt Guy , Rosenquist Richard , Ashton-Key Margaret , Forconi Francesco , Collins Andrew , Ghia Paolo , Matutes Estella , Pangalis Gerassimos , Stamatopoulos Kostas , Oscier David , Strefford Jonathan C.
Published: April 2023

Supplementary Figure 1. Additional gene maps
Supplemental Tables 1-4 from EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Authors: Ercan Dalia , Choi Hwan Geun , Yun Cai-Hong , Capelletti Marzia , Xie Ting , Eck Michael J. , Gray Nathanael S. , Jänne Pasi A.
Published: April 2023

Supplemental Tables 1-4. Table S1. Secondary EGFR mutations recovered in the presence of WZ4002. Table S2. Efficacy (IC50 values) of EGFR kinase inhibitors in EGFR mutant Ba/F3 cells Table S3. Efficacy (IC50 values) of covalent EGFR kinase inhibitors in EGFR mutant Ba/F3 cells or lung cancer cell lines. Table S4. Frequency and type of EGFR secondary mutation following ENU mutagenesis screen using irreversible pyrimidine EGFR inhibitors.
Supplementary Table 1, Figures S1-4 from CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer
Authors: Svensson Susanne , Abrahamsson Annelie , Rodriguez Gabriela Vazquez , Olsson Anna-Karin , Jensen Lasse , Cao Yihai , Dabrosin Charlotta
Published: April 2023

Supplementary Table 1, Figures S1-4. Supplementary Table 1. Characteristics of patients that underwent intratumoral microdialysis. All cancers were HER-2-negative. Figure S1. Neutrophil infiltration in experimental breast cancer Figure S2. Tamoxifen decreased macrophage infiltration into ER+ breast and ovarian cancer explants. Figure S3. CCR receptors expressed in the murine breast cancer models. Figure S4. Schematic illustration of estrogen-dependent mechanisms of breast cancer progression.
Supplemental table S1 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study
Authors: Fox Peter , Balleine Rosemary L. , Lee Clara , Gao Bo , Balakrishnar Bavanthi , Menzies Alexander M. , Yeap Shang Heng , Ali Sayed Sahanawaz , Gebski Val , Provan Pamela , Coulter Sally , Liddle Christopher , Hui Rina , Kefford Richard , Lynch Jodi , Wong Mark , Wilcken Nicholas , Gurney Howard
Published: April 2023

CYP2D6 genotype and phenotype for each subject
Supplemental figure 1 legend from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study
Authors: Fox Peter , Balleine Rosemary L. , Lee Clara , Gao Bo , Balakrishnar Bavanthi , Menzies Alexander M. , Yeap Shang Heng , Ali Sayed Sahanawaz , Gebski Val , Provan Pamela , Coulter Sally , Liddle Christopher , Hui Rina , Kefford Richard , Lynch Jodi , Wong Mark , Wilcken Nicholas , Gurney Howard
Published: April 2023

Legend for Supplemental figure 1
Supplemental figure 1 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study
Authors: Fox Peter , Balleine Rosemary L. , Lee Clara , Gao Bo , Balakrishnar Bavanthi , Menzies Alexander M. , Yeap Shang Heng , Ali Sayed Sahanawaz , Gebski Val , Provan Pamela , Coulter Sally , Liddle Christopher , Hui Rina , Kefford Richard , Lynch Jodi , Wong Mark , Wilcken Nicholas , Gurney Howard
Published: April 2023

Change in tamoxifen and metabolite levels in response to tamoxifen dose increase
Supplemental Figure 4 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
Authors: Martínez-Vélez Naiara , Xipell Enric , Vera Beatriz , Acanda de la Rocha Arlet , Zalacain Marta , Marrodán Lucía , Gonzalez-Huarriz Marisol , Toledo Gemma , Cascallo Manel , Alemany Ramón , Patiño Ana , Alonso Marta M.
Published: April 2023

Supplemental Figure 4
Supplemental Figure 3 from The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma
Authors: Martínez-Vélez Naiara , Xipell Enric , Vera Beatriz , Acanda de la Rocha Arlet , Zalacain Marta , Marrodán Lucía , Gonzalez-Huarriz Marisol , Toledo Gemma , Cascallo Manel , Alemany Ramón , Patiño Ana , Alonso Marta M.
Published: April 2023

Supplemental Figure 3
Supplementary Figure 2 from Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Authors: Al-Ejeh Fares , Pajic Marina , Shi Wei , Kalimutho Murugan , Miranda Mariska , Nagrial Adnan M. , Chou Angela , Biankin Andrew V. , Grimmond Sean M. , Brown Michael P. , Khanna Kum Kum
Published: April 2023

Supplementary Figure 2: Maximum tolerated doses of gemcitabine, Chk1i and EGFR-directed RIT in vivo. (A) Balb/c nude mice bearing PANC-1 subcutaneous xenografts (60 mm3 in volume) were treated with 50 mg/kg or 100 mg/kg of gemcitabine on days 1, 4, 7 and 10 administered intravenously combined with 15 mg/kg Chk1i, administered as two doses per day (7.5 mg/kg per dose) on days 1, 4, 7 and 10 at 3 hours before and after gemcitabine administration. Mice were treated with gemcitabine and Chk1i combinations (gem + Chk1i) alone or in combination with 6 or 9 MBq/20g (300 or 450 MBq/kg) of 177Lu-anti-EGFR mAb. Mice were monitored for 14 days to determine acute toxicities as judged by weight, posture, movement, eating and drinking. Tumor volume was also monitored during this short time as an indication of efficacy. (B) The tumor growth curves were used to measure the growth rate (k = day-1) from exponential growth equations and shown in the bar graph in panel (5 mice per group, error bar is the standard error of the mean, SEM). *** p < 0.001 in One-way ANOVA in GraphPad® Prism comparing treatments involving anti-EGFR RIT and those not involving this RIT (p<0.001). No statistical differences were observed amongst treatments involving the anti-EGFR RIT.
Supplementary Figure 1 from Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma
Authors: Al-Ejeh Fares , Pajic Marina , Shi Wei , Kalimutho Murugan , Miranda Mariska , Nagrial Adnan M. , Chou Angela , Biankin Andrew V. , Grimmond Sean M. , Brown Michael P. , Khanna Kum Kum
Published: April 2023

Supplementary Figure 1: Sensitization of PANC-1 cells to gemcitabine and EGFR-directed RIT by Chk1 inhibition. (A) Adherent cultures of the PDAC PANC-1 cell line were treated in the absence or presence of escalating doses of gemcitabine, in the absence of presence of Chk1i alone (PF-477736, 180 nM) or the combinations. Chk1i was added either 16 hours after gemcitabine or concurrently. Cells were collected 24-96 hours after treatment for standard cell cycle analysis by DNA content using FACS. (B) PANC-1 cells were treated with escalating concentrations of 177Lu-anti-EGFR mAb (RIT) to achieve the specified radiation doses (0-4 Gy) over 72 hours of incubation. RIT was performed alone or in combination with Chk1i (180 nM) and then clonogenic survival was determined by standard assays. Chk1i alone at 180 nM did not have any effect on clonogenic survival (data not shown). (C) PANC-1 cells were left untreated (vehicle control, data not shown) or incubated with anti-EGFR mAb (unlabeled, control which was not different from the vehicle control), 177Lu-DOTA, 177Lu-labelled mAb with irrelevant specificity (Sal5, raised against Salmonella antigen) or 177Lu-anti-EGFR mAb (2 Gy over 72 hours). Cells were washed 3 hours after incubation to remove unbound material and left untreated or treated with Chk1i alone (180 nM), gemcitabine alone (40 ng/mL) or the combination (Chk1i+gemcitabine) before standard clonogenic survival assays.
Supplementary Figure Legends from Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival
Authors: Reed Caroline M. , Cresce Nicole D. , Mauldin Ileana S. , Slingluff Craig L. , Olson Walter C.
Published: April 2023

Supplementary Figure Legends. Legends for supplementary figures.
Supplementary Figures 1-2, Supplementary Tables 1-2 from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer
Authors: Stewart Grant D. , O'Mahony Fiach C. , Laird Alexander , Eory Lel , Lubbock Alexander L.R. , Mackay Alan , Nanda Jyoti , O'Donnell Marie , Mullen Peter , McNeill S. Alan , Riddick Antony C.P. , Berney Daniel , Bex Axel , Aitchison Michael , Overton Ian M. , Harrison David J. , Powles Thomas
Published: April 2023

Supplementary Figures 1-2, Supplementary Tables 1-2. Fig. S1. Histogram showing lack of correlation between differential protein and RNA expression levels between sunitinib naive and treated patient samples; Figure S2: Dendrograms illustrating supervised Euclidean clustering of copy number variations (AC) and gene expression (D-F) for driver mutation genes (A+D), hypoxia genes (B+E) and stromal genes (C+F); Table S1: Validated antibodies used in RPPA experiments; Table S2: Differential expression of each protein in sunitinib naive and treated samples as evaluated by RPPA (1-8).
Supplementary Table 6 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

Gene Set Enrichment Analysis (GSEA) of genes differentially expressed between Class1PRAME+ tumors and Class1PRAME- tumors with respect to molecular function.
Supplementary Figure 2 from PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Authors: Field Matthew G. , Decatur Christina L. , Kurtenbach Stefan , Gezgin Gülçin , van der Velden Pieter A. , Jager Martine J. , Kozak Kaleigh N. , Harbour J. William
Published: April 2023

GViz integrated chromosomal visualization plots.
Supplemental Figure 1 from Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination
Authors: Jackson Christopher M. , Kochel Christina M. , Nirschl Christopher J. , Durham Nicholas M. , Ruzevick Jacob , Alme Angela , Francica Brian J. , Elias Jimmy , Daniels Andrew , Dubensky Thomas W. , Lauer Peter , Brockstedt Dirk G. , Baxi Emily G. , Calabresi Peter A. , Taube Janis M. , Pardo Carlos A. , Brem Henry , Pardoll Drew M. , Lim Michael , Drake Charles G.
Published: April 2023

Brain and flank tumors are of equivalent mass. Brain and flank tumor mass was not different on day 17 when tissues were harvested for analysis. Experiment conducted x 2 with {greater than or equal to} 5 mice/group.
Supplementary Table 3 from Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance
Authors: Zhang Hanwei , Prado Kris , Zhang Kelvin X. , Peek Elizabeth M. , Lee Jane , Wang Xiaoyan , Huang Jiaoti , Li Gang , Pellegrini Matteo , Chin Arnold I.
Published: April 2023

Table 3 lists is an Excel file listing genes shared between p-53-like gene and subtype II, SW780Foxop3del3 and p53-like and HT1376Foxp3del3 and p53-like.
Analysis of LPACs and non-LPACs based on various stem cell markers. from Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Authors: Munakata Koji , Uemura Mamoru , Tanaka Shinji , Kawai Kenji , Kitahara Tomohiro , Miyo Masaaki , Kano Yoshihiro , Nishikawa Shinpei , Fukusumi Takahito , Takahashi Yusuke , Hata Taishi , Nishimura Junichi , Takemasa Ichiro , Mizushima Tsunekazu , Ikenaga Masakazu , Kato Takeshi , Murata Kohei , Carethers John M. , Yamamoto Hirofumi , Doki Yuichiro , Mori Masaki
Published: April 2023

Described markers expression, CD133, CD166, Lgr5 (Alexa FluorÂ® 647 channel, BD Biosciences) and EpHB2 (PE channel, R&D systems, Minneapolis, MN, USA), were compared between LPACs and non-LPACs. The LPACs clearly showed up-regulation of several CSC markers including CD133, CD166, Lgr5 and EpHB2. Especially, Lgr5 was enriched in all cell lines (HCT116; 0.7% (non-LPACs) vs 18.1% (LPACs), SW480; 0.2% vs 28.1% and DLD1; 2.3% vs 45.2%).
Supplemental Information from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Information. Validation Set Sample IDs
Supplemental Data Figure Legends from Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma
Authors: Hirbe Angela C. , Dahiya Sonika , Miller Christopher A. , Li Tiandao , Fulton Robert S. , Zhang Xiaochun , McDonald Sandra , DeSchryver Katherine , Duncavage Eric J. , Walrath Jessica , Reilly Karlyne M. , Abel Haley J. , Pekmezci Melike , Perry Arie , Ley Timothy J. , Gutmann David H.
Published: April 2023

Supplemental Data Figure Legends
Supplementary Table and Figure Legends from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Authors: Leary Alexandra , Evans Abigail , Johnston Stephen R.D. , A'Hern Roger , Bliss Judith M. , Sahoo Rashmita , Detre Simone , Haynes Benjamin P. , Hills Margaret , Harper-Wynne Catherine , Bundred Nigel , Coombes Gill , Smith Ian , Dowsett Mitch
Published: April 2023

Supplementary Table and Figure Legends. A list of all the supplementary table and figure legends.
Supplementary Table 4 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Authors: Leary Alexandra , Evans Abigail , Johnston Stephen R.D. , A'Hern Roger , Bliss Judith M. , Sahoo Rashmita , Detre Simone , Haynes Benjamin P. , Hills Margaret , Harper-Wynne Catherine , Bundred Nigel , Coombes Gill , Smith Ian , Dowsett Mitch
Published: April 2023

Supplementary Table 4. Correlation of change in protein and mRNA biomarker values with change in Ki67 for both lapatinib-treated and placebo-treated control patients.
Supplementary Table S2 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Authors: Rodriguez Pedro C. , Popa Xitllaly , Martínez Odeth , Mendoza Silvia , Santiesteban Eduardo , Crespo Tatiana , Amador Rosa M. , Fleytas Ricardo , Acosta Soraida C. , Otero Yanine , Romero Gala N. , de la Torre Ana , Cala Mireysi , Arzuaga Lina , Vello Loisel , Reyes Delmairis , Futiel Niurka , Sabates Teresa , Catala Mauricio , Flores Yoanna I. , Garcia Beatriz , Viada Carmen , Lorenzo-Luaces Patricia , Marrero Maria A. , Alonso Liuba , Parra Jenelin , Aguilera Nadia , Pomares Yaisel , Sierra Patricia , Rodríguez Gryssell , Mazorra Zaima , Lage Agustin , Crombet Tania , Neninger Elia
Published: April 2023

Overview of all adverse events in the safety evaluable population.
Supplementary Table 3 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Authors: Rodriguez Pedro C. , Popa Xitllaly , Martínez Odeth , Mendoza Silvia , Santiesteban Eduardo , Crespo Tatiana , Amador Rosa M. , Fleytas Ricardo , Acosta Soraida C. , Otero Yanine , Romero Gala N. , de la Torre Ana , Cala Mireysi , Arzuaga Lina , Vello Loisel , Reyes Delmairis , Futiel Niurka , Sabates Teresa , Catala Mauricio , Flores Yoanna I. , Garcia Beatriz , Viada Carmen , Lorenzo-Luaces Patricia , Marrero Maria A. , Alonso Liuba , Parra Jenelin , Aguilera Nadia , Pomares Yaisel , Sierra Patricia , Rodríguez Gryssell , Mazorra Zaima , Lage Agustin , Crombet Tania , Neninger Elia
Published: April 2023

Related adverse events in the vaccine arm. Number of adverse events.
Supplementary Figure 3 from Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Authors: Leary Alexandra , Evans Abigail , Johnston Stephen R.D. , A'Hern Roger , Bliss Judith M. , Sahoo Rashmita , Detre Simone , Haynes Benjamin P. , Hills Margaret , Harper-Wynne Catherine , Bundred Nigel , Coombes Gill , Smith Ian , Dowsett Mitch
Published: April 2023

Supplementary Figure 3. Correlations between Ki67 response and expression of epiregulin in HER2+ lapatinib-treated cases
Supplementary Figure 4 from Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
Authors: Luchman H. Artee , Stechishin Owen D.M. , Nguyen Stephanie A. , Lun Xueqing Q. , Cairncross J. Gregory , Weiss Samuel
Published: April 2023

AZD and TMZ administration do not significantly influence body weights of treated animals.
Supplementary Figure 1 from Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Authors: Zhang Libo , Marrano Paula , Wu Bing , Kumar Sushil , Thorner Paul , Baruchel Sylvain
Published: April 2023

Limited anti-tumor effects of ifosfamide in the CHLA-20 xenograft model. A total of 1 Ã- 106 CHLA-20 cells were implanted subcutaneously into SCID/SCID mice. Once tumors were palpable (about 0.25cm3), mice were randomized into vehicle control (n=6) or ifosfamide treatment group (n = 6 for each group). Ifosfamide was administered intraperitoneally at 50 mg/kg five times a week. After 2 weeks, there was slightly delay of tumor growth with ifosfamide treatment, but the difference between control tumors and ifosfamide group was not statistically significant (p>0.05).
supplemental figure legend from Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Authors: Kluger Harriet M. , Zito Christopher R. , Barr Meaghan L. , Baine Marina K. , Chiang Veronica L.S. , Sznol Mario , Rimm David L. , Chen Lieping , Jilaveanu Lucia B.
Published: April 2023

supplemental figure legend
Supplementary Figure 1 from Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites
Authors: Kluger Harriet M. , Zito Christopher R. , Barr Meaghan L. , Baine Marina K. , Chiang Veronica L.S. , Sznol Mario , Rimm David L. , Chen Lieping , Jilaveanu Lucia B.
Published: April 2023

Supplementary Figure 1. Immunoblotting for PD-L1. A band can be seen in the Mel624 cells stably transfected with PD-L1, but not in the untransfected control. Other melanoma cultures show variable PD-L1 levels. Equal protein gel loading was assessed by probing for expression of β-actin.
Supplementary Figure S3 from Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2
Authors: Terashima Masato , Togashi Yosuke , Sato Katsuaki , Mizuuchi Hiroshi , Sakai Kazuko , Suda Kenichi , Nakamura Yu , Banno Eri , Hayashi Hidetoshi , De Velasco Marco A. , Fujita Yoshihiko , Tomida Shuta , Mitsudomi Tetsuya , Nishio Kazuto
Published: April 2023

Growth inhibitory effect of collagen via the activation of the p38 signal in A549-DDR2 S768R. (A) Cellular proliferation of transfectant A549 cell lines. Cellular growth was examined using an MTT assay with or without stimulation with collagen I (10 µg/mL). Without collagen I, the cellular proliferation of A549-DDR2 S768R was significantly enhanced, compared with the controls. In contrast, under exposure to collagen I, the cellular proliferation was particularly reduced, similar to that in the A549-DDR2 WT cell line. Furthermore, the proliferation of the A549-DDR2 E655K cell line was significantly enhanced, compared with that of A549-DDR2 S768R cell line, under exposure to collagen I. Columns, mean of independent triplicate experiments; Bars, SD; *, P < 0.05; n.s., not significant. (B) Western blotting of the MAPK signal pathways in the A549-S768R cell line. The phosphorylation of ERK1/2, c-Jun, or JNK were not enhanced after exposure to collagen I. In contrast, the phosphorylation of p38 in the A549-DDR2 S768R cell line was enhanced 6 or 24 hours after stimulation with collagen I. β-actin was used as an internal control. (C) Cellular proliferation of the A549-DDR2 S768R cell lines with or without exposure to a p38 inhibitor (SB202190, 1 µM) in the presence of collagen I (10 µg/mL). Cellular growth was examined using an MTT assay. When the A549-DDR2 S768R cell line was treated with SB202190, the suppression of proliferation by collagen stimulation was cancelled. Columns, mean of independent triplicate experiments; Bars, SD; *P < 0.05.
Supplementary Table S1 from A Hypoxia-Induced Vascular Endothelial-to-Mesenchymal Transition in Development of Radiation-Induced Pulmonary Fibrosis
Authors: Choi Seo-Hyun , Hong Zhen-Yu , Nam Jae-Kyung , Lee Hae-June , Jang Junho , Yoo Ran Ji , Lee Yong Jin , Lee Chang Young , Kim Kyung Hwan , Park Seungwoo , Ji Young Hoon , Lee Yun-Sil , Cho Jaeho , Lee Yoon-Jin
Published: April 2023

Supplementary Table S1. The clinicopathologic characteristics of lung cancer patients analyzed in this study
Table S5 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Table S5. Variants, copy number alterations and rearrangements identified in 24 samples by targeted next generation sequencing (NGS). In the copy number alterations column samples were classified based on gene copy number in two: (A) = amplified (> 2 copies of the gene) and (L) = Low (< 2 copies of the gene). Sample 2 is reported in the main text as CG-42.
Table S3 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Table S3. Specific mutations identified in HER2, KRAS and BRAF genes.
Table S1 from Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Authors: Capelletti Marzia , Dodge Michael E. , Ercan Dalia , Hammerman Peter S. , Park Seung-Il , Kim Jhingook , Sasaki Hidefumi , Jablons David M. , Lipson Doron , Young Lauren , Stephens Phil J. , Miller Vincent A. , Lindeman Neal I. , Munir Kiara J. , Richards William G. , Jänne Pasi A.
Published: April 2023

Table S1. List of the primers used to screen for the known genetic rearrangements.
Supplemental Figures 1-6 from Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas
Authors: Toledo Rodrigo A. , Qin Yuejuan , Cheng Zi-Ming , Gao Qing , Iwata Shintaro , Silva Gustavo M. , Prasad Manju L. , Ocal I. Tolgay , Rao Sarika , Aronin Neil , Barontini Marta , Bruder Jan , Reddick Robert L. , Chen Yidong , Aguiar Ricardo C.T. , Dahia Patricia L.M.
Published: April 2023

Supplemental Figure 1: Alternative views of Figure 1 displaying mutations in our cohort; Supplemental Figure 2: Histone 3.3 G34W mutation in patient samples; Supplemental Figure 3: In silico analysis of histone 3.3 and G34W mutant; Supplemental Figure 4: Immunohistochemistry of trimethylated Histone 3; Supplemental Figure 5: Expression profiling of pheochromocytomas and paragangliomas with a H3F3A mutation; Supplemental Figure 6: Familial pheochromocytoma segregating with a MET gene mutation
Sup Figure 4 from Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
Authors: Yap Timothy A. , Yan Li , Patnaik Amita , Tunariu Nina , Biondo Andrea , Fearen Ivy , Papadopoulos Kyriakos P. , Olmos David , Baird Richard , Delgado Liliana , Tetteh Ernestina , Beckman Robert A. , Lupinacci Lisa , Riisnaes Ruth , Decordova Shaun , Heaton Simon P. , Swales Karen , deSouza Nandita M. , Leach Martin O. , Garrett Michelle D. , Sullivan Daniel M. , de Bono Johann S. , Tolcher Anthony W.
Published: April 2023

Sup Figure 4. A 42-year-old female with metastatic breast cancer treated with 60mg QOD of MK-2206.
Supplementary Figures S1-10 from Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas
Authors: Li Sichen , Chowdhury Reshmi , Liu Fei , Chou Arthur P. , Li Tie , Mody Reema R. , Lou Jerry J. , Chen Weidong , Reiss Jean , Soto Horacio , Prins Robert , Liau Linda M. , Mischel Paul S. , Nghiemphu Phioanh L. , Yong William H. , Cloughesy Timothy F. , Lai Albert
Published: April 2023

Supplementary Figures S1-10. Figure S1. RRBS methylation results of full miR-148a-associated CpG island. Figure S2. The methylation status of IDH1 mutation is prognostic in GBM and Anaplastic Astrocytoma (Grade III). Figure S3. miR-148a promotor CpG island was demethylated and expression was upregulated after demethylating agent 5-aza-CdR treatment. Figure S4. Knockdown of DNMT1 in U251 cells by using siRNA. Figure S5. Introduction of mutant IDH1 into HEK293T. Figure S6. Overexpression of miR-148a in 293T-IDH1MUT doesn't block the methylation of miR-148a and RBP1. Figure S7. miR-148a expression level in miR-148a stably transfected U251 and T98G cells. Figure S8. Cell cycle analysis of T98G-miR-148a stable cells. Figure S9. The expression of G-CIMP genes DLC1 and CIDEB are downregulated in IDH1MUT GBM patient tissue samples and glioma cell lines. Figure S10. Model summarizing the role of miR-148a in IDH1 mutant gliomas.
Supplementary data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Authors: Shi Liangrong , Chen Lujun , Wu Changping , Zhu Yibei , Xu Bin , Zheng Xiao , Sun Mingfen , Wen Wen , Dai Xichao , Yang Min , Lv Quansheng , Lu Binfeng , Jiang Jingting
Published: April 2023

Supplemental figure 1. Patient cohort and study design. Supplemental Figure 2. Immunochemical staining of PD-L1 antibody (1:500, clone: SP142) on the paraffin-embedded human melanoma and placenta tissues. Supplemental Figure 3. RFA of colorectal liver metastases increased PD-L1 expression on infiltrating immune cells. Supplemental Figure 4. Correlation between PD-L1 expression on tumor cells and the intensity of CD8+, CD4+ T cell infiltration in endoscopic biopsy (A, B) and resected tumor specimen (C, D) (all of 78 patients were included). Supplemental Figure 5. RFA increased CD45+ immune cells and T cells infiltrating into contralateral tumor. Supplemental Figure 6. RFA increased T cells infiltration and PD-1/PD-L1 expression in a disdant tumor in B16 tumor-bearing mice. Supplemental Figure 7. RFA did not upregulate PD-1/PD-L1 expression in splenic lymphocytes. Supplemental Figure 8. RFA increased Tim-3, CD160, CD244 and eomes expression in a disdant tumor in CT26 tumor-bearing mice. Supplemental Figure 9. RFA and the anti-PD-1 therapy increased CD8+TIL cell infiltration in distant tumor. Supplemental Figure 10. RFA and the anti-PD-1 therapy upregulated Tim-3 expression on T cells in a distant tumor. Supplemental Table 1 Primer sequences used for the detection of gene expression by RT-QPCR Supplemental Table 2 Patient characteristic Supplemental table 3. Multivariate analysis of factors related to increased PD-L1 expression in resected tumor specimen.
Supplementary Materials and Methods, Figures 1 - 13, Table 1 from Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies
Authors: Deniger Drew C. , Maiti Sourindra N. , Mi Tiejuan , Switzer Kirsten C. , Ramachandran Vijaya , Hurton Lenka V. , Ang Sonny , Olivares Simon , Rabinovich Brian A. , Huls M. Helen , Lee Dean A. , Bast Robert C. , Champlin Richard E. , Cooper Laurence J.N.
Published: April 2023

PDF file - 1405KB, Supplementary Materials and Methods. Supplementary Figures - (1) Tumor cell line culture conditions and media formulations (2) Co-culture conditions for gamma/delta T cells and designer aAPC (3) Intracellular cytokine production, Luminex, and neutralizing antibody cytolysis assays (4) Lentivirus packaging and transduction of CAOV3 cells Contents of the Supplemental Data include figures: (1) An example of the gating strategy for gamma/delta T-cell analyses (2) Schematic of DNA plasmid pLVU3G-effLuc-T2A-mKateS158A used to co-express enhanced firefly luciferase (effLuc) and mKate (3) Expression of activation markers CD38 and CD95 on propagated gamma/delta T cells (4) aAPC developed for co-culture with gamma/delta T cells to determine the impact of introduced co-stimulatory molecules (5) Expansion of UCB-derived gamma/delta T cells on aAPC with IL-2 and IL-21 (6) Surface expression of TCRdelta1 and TCRdelta2 chains on gamma/delta T cells derived from PBMC prior to propagation (7) Abundance of Vdelta and Vgamma mRNA species in gamma/delta T cells prior to ex vivo numeric expansion (8) Surface expression of TCRdelta1 and TCRdelta2 chains on gamma/delta T cells derived from UCB and propagated on aAPC with IL-2 and IL-21 (9) mRNA expression of shared Valpha/Vdelta alleles in gamma/delta T cells separated and then propagated on aAPC, IL-2, and IL-21 (10) Abundance of mRNA species coding for Vgamma chains in gamma/delta T-cell subsets (11) In vitro lysis of tumor cell line panel by polyclonal gamma/delta T cells (12) Specific lysis of hematological and solid tumor cells by Vdelta T-cell subsets (13) Immunophenotypes associated with PBMC-derived Vdelta T-cell subsets expanded on aAPC/IL-2/IL-21. Supplemental Table 1 - details the antibodies used in this study, where they were purchased, and their hybridoma clone.
Supplementary table 3 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Authors: Moreno García Victor , Olmos David , Gomez-Roca Carlos , Cassier Philippe A. , Morales-Barrera Rafael , Del Conte Gianluca , Gallerani Elisa , Brunetto Andre T. , Schöffski Patrick , Marsoni Silvia , Schellens Jan H.M. , Penel Nicolas , Voest Emile , Evans Jeffrey , Plummer Ruth , Wilson Richard H. , Soria Jean Charles , Tabernero Josep , Verweij Jaap , Kaye Stan B.
Published: April 2023

Supplementary table 3. Multivariate model for Overall Survival (Cytotoxic Agents)
Supplementary table 1 from Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Authors: Moreno García Victor , Olmos David , Gomez-Roca Carlos , Cassier Philippe A. , Morales-Barrera Rafael , Del Conte Gianluca , Gallerani Elisa , Brunetto Andre T. , Schöffski Patrick , Marsoni Silvia , Schellens Jan H.M. , Penel Nicolas , Voest Emile , Evans Jeffrey , Plummer Ruth , Wilson Richard H. , Soria Jean Charles , Tabernero Josep , Verweij Jaap , Kaye Stan B.
Published: April 2023

Supplementary table 1. Main characteristics of patients receiving different dose levels
Supplementary Table 1 from Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60
Authors: Reinhold William C. , Sunshine Margot , Varma Sudhir , Doroshow James H. , Pommier Yves
Published: April 2023

Supplementary Table 1. Cell line data comparison across three institutes
Supplementary Figure 1 from Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60
Authors: Reinhold William C. , Sunshine Margot , Varma Sudhir , Doroshow James H. , Pommier Yves
Published: April 2023

Supplementary Figure 1. The "Cross-correlations" and "Pattern comparison" tools
Supplemental Figures 1-5 from Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Cervantes-Gomez Fabiola , Lamothe Betty , Woyach Jennifer A. , Wierda William G. , Keating Michael J. , Balakrishnan Kumudha , Gandhi Varsha
Published: April 2023

Supplemental Figures 1-5. Figure S1. Effect of ibrutinib treatment during in-vitro incubation of CLL cells on levels of antiapoptotic proteins MCL-1, BCL-XL, and BCL-2; Figure S2. Effect of ibrutinib in-vitro treatment on transcript levels of antiapoptotic proteins MCL-1, BCL-XL, and BCL-2; Figure S3. In vitro ABT-199-mediated cytotoxicity in lymphocytes from CLL patients treated with ibrutinib for 36 weeks; Figure S4. Changes in the expression levels of BTK pathway proteins in CLL cells from six CLL patient samples before and after ibrutinib therapy; Figure S5. Cytotoxicity elicited by ABT-199 in combination with ibrutinib in lymphocytes from a TCL1 mouse adoptive transfer model of CLL.
Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Authors: Jethava Yogesh S. , Mitchell Alan , Epstein Joshua , Zangari Maurizio , Yaccoby Shmuel , Tian Erming , Waheed Sarah , Khan Rashid , Papanikolaou Xenofon , Grazziutti Monica , Cottler-Fox Michele , Petty Nathan , Steward Douglas , Panozzo Susan , Bailey Clyde , Hoering Antje , Crowley John , Sawyer Jeffrey , Morgan Gareth , Barlogie Bart , van Rhee Frits
Published: April 2023

Supplementary Table 1: Total Therapy 4 (TT4) protocol schema Supplementary Table 2: Adverse Events by Arm and Maximum NCI CTC Grade Supplementary Table 3: Top 51 gene probes distinguishing multiple myeloma with and without cytogenetic abnormalities (CA)
Gilbert et al Suppl data from Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma
Authors: Gilbert Duncan C. , Al-Saadi Reem , Thway Khin , Chandler Ian , Berney Daniel , Gabe Rhian , Stenning Sally P. , Sweet Joan , Huddart Robert , Shipley Janet M.
Published: April 2023

Table S1. Canadian tissue microarray, histology and relapse rate details. Table S2. Univariate, stratified and multivariate models for prognostic ability of VI, CXCL12 expression. Table S3. Multivariate analyses; alternative models. Figure S1: Kaplan-Meier relapse-free survival curves in combined TE08 and TE22 trial cohorts with (n=190) and without FFPE (n=501). Figure S2: Relapse-free rate by CXCL12 intensity (<10%=absent) and Vascular Invasion.
Supplementary Tables 1-17, Figures 1-14, Methods from Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Authors: Pusztai Lajos , Moulder Stacy , Altan Mehmet , Kwiatkowski Danielle , Valero Vicente , Ueno Naoto T. , Esteva Francisco J. , Avritscher Rony , Qi Yuan , Strauss Lewis , Hortobagyi Gabriel N. , Hatzis Christos , Symmans W. Fraser
Published: April 2023

Supplemental Table 1: Probe sets used in dasatinib 19-gene dasatinib target index. Supplemental Table 2: Probe sets used in Src Pathway index. Supplemental Table 3: Probe sets used in the Cell Line Derived Sensitivity predictor. Supplemental Table 4: Agreement between predictors. Supplemental Table 5: QC metrics for the 39 FNA samples used for replicate hybridization (technical replicates). Supplemental Table 6: QC metrics for the 37 paired FNA/CBX samples and 6 replicate CBX samples. Supplemental Table 7: Concordance correlation coefficients for prediction scores. Supplemental Table 8: Prediction results on 39 FNA pairs. Supplemental Table 9: Prediction results on 37 FNA/CBX pairs. Supplemental Table 10: Prediction results on 6 CBX pairs. Supplemental Table 11: Prediction results for the 133 breast cancer samples. Supplemental Table 12: Concordance correlation coefficients with revised average expression-based Src pathway. Supplemental Table 13: Prediction results on 39 FNA pairs (revised Src pathway). Supplemental Table 14: Prediction results on 37 FNA/CBX pairs (revised Src pathway. Supplemental Table 15: Prediction results on 6 CBX pairs (revised Src pathway). Supplemental Table 16: Individual prediction scores for the 23 BMS cell lines. Supplementary Table 17. Clinical characteristics of the 133 patients included in the training data set. Supplemental Figure 1: Overall index distribution of Dasatinib 19-gene target index. Supplemental Figure 2: Agreements between 3 predictors. Supplemental Figure 3: Replicate FNA (N=39). Supplemental Figure 4: Matching FNA/CBX pairs from same tumor (N=37). Supplemental Figure 5: FNA/CBX cohort pairs (N=29). Supplemental Figure 6: FNA/CBX ANON pairs (N=8). Supplemental Figure 7: CBX pairs from same tumor (N=6). Supplemental Figure 8: Concordance for 39 FNA pairs using expression values of individual probes. Supplemental Figure 9: Concordance for 39 FNA pairs using the expression values of subset probes. Supplemental Figure 10:Multi-Dimension Scaling (MDS) analysis with the cell lines used to develop the Src index and the MDACC 133 patients. Supplemental Figure 11. Revised SRC Pathway activity score distribution in the reference population. Supplemental Figure 12 Overlap between the 3 different prediction results. Supplemental Figure 13: Dasatinib 19-genes target index on 23 BMS cell lines with known dasatinib sensitivity. Supplemental Figure 14: Revised Src pathway score on 23 BMS cell lines with known dasatinib sensitivity.
Supplemental Materials and Methods from A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment
Authors: Witney Timothy H. , Hoehne Aileen , Reeves Robert E. , Ilovich Ohad , Namavari Mohammad , Shen Bin , Chin Frederick T. , Rao Jianghong , Gambhir Sanjiv S.
Published: April 2023

Supplemental Materials and Methods. A detailed description of the radiosynthesis of each radiotracer, and detailed PET and SPECT imaging protocols.
Supplemental Table 2 from IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Authors: Vallera Daniel A. , Felices Martin , McElmurry Ron , McCullar Valarie , Zhou Xianzheng , Schmohl Joerg Uwe , Zhang Bin , Lenvik Alexander J. , Panoskaltsis-Mortari Angela , Verneris Michael R. , Tolar Jakub , Cooley Sarah , Weisdorf Daniel J. , Blazar Bruce R. , Miller Jeffrey S.
Published: April 2023

Blocking studies show specificity of BiKEs and TriKEs.
Supplementary Figure S4 from Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Authors: Kageyama Shinichi , Ikeda Hiroaki , Miyahara Yoshihiro , Imai Naoko , Ishihara Mikiya , Saito Kanako , Sugino Sahoko , Ueda Shugo , Ishikawa Takeshi , Kokura Satoshi , Naota Hiroaki , Ohishi Kohshi , Shiraishi Taizo , Inoue Naoki , Tanabe Masashige , Kidokoro Tomohide , Yoshioka Hirofumi , Tomura Daisuke , Nukaya Ikuei , Mineno Junichi , Takesako Kazutoh , Katayama Naoyuki , Shiku Hiroshi
Published: April 2023

Phenotypes of MAGE-A4-tetramer+/CD8+ T cells after TCR gene-transduced T-cell transfer.
Supplementary Fig. S1 from Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Authors: Sucker Antje , Zhao Fang , Real Birgit , Heeke Christina , Bielefeld Nicola , Maβen Stefan , Horn Susanne , Moll Iris , Maltaner Raffaela , Horn Peter A. , Schilling Bastian , Sabbatino Francesco , Lennerz Volker , Kloor Matthias , Ferrone Soldano , Schadendorf Dirk , Falk Christine S. , Griewank Klaus , Paschen Annette
Published: April 2023

Supplementary Fig. S1. Analysis of CD3 (T cells) and HMB-45 (melanoma cells) expression in serial sections from cryopreserved metastasis Ma-Mel-48b. Red staining indicates positive cells.
Supplementary Figure SF2 from Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Authors: GuhaThakurta Debraj , Sheikh Nadeem A. , Fan Li-Qun , Kandadi Harini , Meagher T. Craig , Hall Simon J. , Kantoff Philip W. , Higano Celestia S. , Small Eric J. , Gardner Thomas A. , Bailey Kate , Vu Tuyen , DeVries Todd , Whitmore James B. , Frohlich Mark W. , Trager James B. , Drake Charles G.
Published: April 2023

Supplementary Figure SF2. Shown in this figure are four Kaplan-Meier (KM) plots comparing the OS of patients in the sipuleucel-T arm of IMPACT with no IgG response at week 10 (IgG responses = 0) to patients with {greater than or equal to}1 IgG responses (A), {greater than or equal to}2 IgG responses (B), {greater than or equal to}3 IgG responses (C), or {greater than or equal to}4 IgG responses (D) at week 10.
Supplemental Table 1 from Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer
Authors: Yang Ji-Yeon , Werner Henrica M.J. , Li Jie , Westin Shannon N. , Lu Yiling , Halle Mari K. , Trovik Jone , Salvesen Helga B. , Mills Gordon B. , Liang Han
Published: April 2023

Supplemental Table 1. Clinical information and RPPA data on patients in the training set
Supplementary Table 1 from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Supplementary Table 1. Clinical and histologic characteristics of cutaneous melanocytic nevi, primary melanomas, and melanoma metastases and their relationship to ITK protein levels
Supplementary Figure 1 from IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Authors: Carson Craig C. , Moschos Stergios J. , Edmiston Sharon N. , Darr David B. , Nikolaishvili-Feinberg Nana , Groben Pamela A. , Zhou Xin , Kuan Pei Fen , Pandey Shaily , Chan Keefe T. , Jordan Jamie L. , Hao Honglin , Frank Jill S. , Hopkinson Dennis A. , Gibbs David C. , Alldredge Virginia D. , Parrish Eloise , Hanna Sara C. , Berkowitz Paula , Rubenstein David S. , Miller C. Ryan , Bear James E. , Ollila David W. , Sharpless Norman E. , Conway Kathleen , Thomas Nancy E.
Published: April 2023

Supplementary Figure 1. IHC staining for co-localization of immune markers with cells expressing ITK and determining the presence of ITK in immune cell subtypes infiltrating the tumor and the effect of ITK ablation on the cell cycle of the melanoma cells
Supplementary Figure S8 from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

PCNA and p16 immunostaining in tumor of UMSCC47 oral xenografts mice
Supplementary Figure S7 from Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins
Authors: Tanaka Noriaki , Patel Ameeta A. , Wang Jiping , Frederick Mitchell J. , Kalu Nene N. , Zhao Mei , Fitzgerald Alison L. , Xie Tong-xin , Silver Natalie L. , Caulin Carlos , Zhou Ge , Skinner Heath D. , Johnson Faye M. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

AZD-1775 as a single agent shows antitumor activity in HPV+ patient derived xenografts xenograft (PDX).
Supplementary Table S1 from Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Authors: Legat Amandine , Maby-El Hajjami Hélène , Baumgaertner Petra , Cagnon Laurène , Abed Maillard Samia , Geldhof Christine , Iancu Emanuela M. , Lebon Luc , Guillaume Philippe , Dojcinovic Danijel , Michielin Olivier , Romano Emanuela , Berthod Grégoire , Rimoldi Donata , Triebel Frédéric , Luescher Immanuel , Rufer Nathalie , Speiser Daniel E.
Published: April 2023

Patients' characteristics and adverse events list
Supplementary Table 1-6 from DNA Methylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors
Authors: Klajic Jovana , Busato Florence , Edvardsen Hege , Touleimat Nizar , Fleischer Thomas , Bukholm Ida , Børresen-Dale Anne-Lise , Lønning Per Eystein , Tost Jörg , Kristensen Vessela N.
Published: April 2023

Supplementary Table 1-6. Supplementary Table 1: Differentially methylated genes and functions of the genes before/after treatment with doxorubicin and FUMI Supplementary Table 2: Ingenuity Pathway analysis Supplementary Table 3: List and function of the 46 differentially methylated genes Supplementary Table 4: List of the 333 differentially methylated genes Supplementary Table 5: Ingenuity Pathway analysis of the 333 differentially methylated genes Supplementary Table 6: Associations between methylation status and TP53 mutation status
Supplementary Figure legends from DNA Methylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors
Authors: Klajic Jovana , Busato Florence , Edvardsen Hege , Touleimat Nizar , Fleischer Thomas , Bukholm Ida , Børresen-Dale Anne-Lise , Lønning Per Eystein , Tost Jörg , Kristensen Vessela N.
Published: April 2023

Supplementary Figure legends. supplementary data